Cloverfields Capital Group, LP Shattuck Labs, Inc. Call Options Transaction History
Cloverfields Capital Group, LP
- $281 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding STTK
# of Institutions
80Shares Held
28.8MCall Options Held
300Put Options Held
1.2K-
Prosight Management, LP Dallas, TX5.68MShares$6.3 Million5.32% of portfolio
-
Redmile Group, LLC San Francisco, CA5.62MShares$6.23 Million1.28% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.9MShares$3.22 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$2.75 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.4MShares$2.67 Million0.0% of portfolio
About Shattuck Labs, Inc.
- Ticker STTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,382,000
- Market Cap $47M
- Description
- Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...